Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation

Journal of Medical Economics

Volumn 18, Issue 5, 2015, Pages 333-340

  Nelson, Winnie W ^a   Wang, Li ^b   Baser, Onur ^b,c,d   Damaraju, C V ^a   Schein, Jeffrey R ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b STATINMED RESEARCH   (United States)

^c MEF UNIVERSITY   (Turkey)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Atrial fibrillation; Healthcare cost; International normalized ratio; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; ADOLESCENT; BLEEDING; COST; ECONOMICS; GOVERNMENT; HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; STATISTICAL MODEL; THROMBOEMBOLISM; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COSTS AND COST ANALYSIS; FEMALE; HEALTH SERVICES; HEMORRHAGE; HOSPITALIZATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; THROMBOEMBOLISM; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; WARFARIN; YOUNG ADULT;

EID: 84929081329     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.1001851     Document Type: Article

References (27)

1. Shea JB, Sears SF. Cardiology patient pages. A patient's guide to living with atrial fibrillation. Circulation 2008;117:e340-3
2. American Heart Association. What is atrial fibrillation? Available at: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/What-is-Atrial-Fibrillation-AFib-or-AF-UCM-423748-Article.jsp, last reviewed April 16, 2014. Accessed September 12, 2014
3. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):429S-56S
4. Reynolds MR, Essebag V. Economic burden of atrial fibrillation: Implications for Intervention. Am J Pharm Benefits 2012;4:58-65
5. Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
6. Johnson B, Smoyer-Tomic K, Siu K, et al. Readmission among hospitalized patients with nonvalvular atrial fibrillation. Am J Health-Syst Pharm 2013;70:414-22
7. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014 Mar 28. 2014;64(21):2246-80
8. Chambers S, Chadda S, Plumb J. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. 2009. Int J Lab Hem 2010;32:427-42
9. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9
10. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-8
11. Hart RG, Sherman DG, Easton JD, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51:674-81
12. Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17:232-7
13. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of International Normalized Ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37
14. Björholt I, Andersson S, Nilsson GH, et al. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract 2007;8:6-13
15. Song X, Sander SD, Johnson BH, et al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health-Syst Pharm 2012;69:329-38
16. von Elm E, Altman DG, Egger M, et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335: 806-8
17. Waller D. How VA hospitals became the best. Time 2006;168:36-7
18. VA Information Resource Center: VIReC The Researcher's Guide to VA data. Medical SAS datasets. Available at: http://www.virec.research.va.gov/MedSAS/Overview.htm#Data. Accessed May 1, 2014
19. VA Information Resource Center; VIReC Research User Guide: VHA Decision Support System Clinical National Data Extracts. 2nd ed. Hines, IL: US Dept. of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center, Sept. 1, 2009. Available at: http://www.virec.research.va.gov/References/RUG/RUG-DSS-2nd-Ed-er.pdf. Accessed May 1, 2014
20. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
21. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinical settings: a multi-site managedcare study. Ann Pharmacother 2005;39:446-51
22. Limone, BL, Baker WL, Mearns ES, et al. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. J Clin Epidemiol 2014;67:1093-102
23. Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-52
24. Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 2009;27:293-9
25. Aziz F, Corder M, Wolffe J, et al. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011;25:1404-7
26. Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ 2014;348:G2116
27. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72